Skip to main content
TipRanks
Go Ultimate75% OFF
MindImmune Therapeutics logo

MindImmune Therapeutics: Valuation, Funding & Investors

Providence, RI, UShttps://www.mindimmune.com/Therapeutics

MindImmune Therapeutics is a venture-backed biotechnology company developing products that target the immunological drivers of neurodegenerative disease. Its lead program, MITI-101, is designed to block the harmful recruitment of peripheral immune cells into the brain in patients with Alzheimer’s disease and other neurodegenerative conditions.

Leadership & Board

Current Number of Employees
15
Current LinkedIn Followers
1,929

Latest Estimated Valuation

Total Amount Raised
$10M
Total Funding Rounds
1
Latest Funding Amount
$10M
Latest Funding Round
Series A

Employee Trend

MindImmune Therapeutics had 15 employees as of November 16, 2026. The number of employees increased by 0 (0.00%) week-over-week.

15Latest Employee Count
0(0.00%)Week-Over-Week Change
05101520Jul 20, 2026Aug 03, 2026Aug 17, 2026Aug 31, 2026Sep 14, 2026Sep 28, 2026Oct 12, 2026Oct 26, 2026Nov 09, 2026

Social Trend

MindImmune Therapeutics had 1,929 followers as of November 16, 2026. The number of followers increased by 10 (0.52%) week-over-week.

1,929Latest Followers Count
10(0.52%)Week-Over-Week Change
05001,0001,5002,000Jul 20, 2026Aug 03, 2026Aug 17, 2026Aug 31, 2026Sep 14, 2026Sep 28, 2026Oct 12, 2026Oct 26, 2026Nov 09, 2026

Funding Round

Funding DateFunding RoundAmount RaisedPost-Money Valuation
Nov 24, 2025Series A$10.20M―

Investors

Similar Companies

A snapshot of private companies similar to MindImmune Therapeutics, helping you discover and navigate related company profiles.

Related News and Analysis